AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.
MetadataShow full item record
AbstractClinicians tend to underestimate potential modest benefits of chemotherapy. They are often reluctant to refer patients for chemotherapy, perhaps because they expect the side effects to outweigh any perceived benefits. However, patients are much more ready to accept chemotherapy, even when the likely benefits are small. Quality of life, change in performance status, and relief of tumor-related symptoms are important additional parameters of treatment assessment. Taking account of these other factors will help clinicians balance quality and quantity of life in patients with metastatic non-small cell lung cancer.
CitationAggressive vs nonaggressive therapy for metastatic NSCLC. 1996, 109 (5 Suppl):87S-92S Chest
- [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
- Authors: Słowik-Gabryelska A, Szczepanik A, Kalicka A
- Issue date: 1999 Jan
- Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
- Authors: Lopez PG, Stewart DJ, Newman TE, Evans WK
- Issue date: 1997
- The role of neoadjuvant chemotherapy in NSCLC.
- Authors: Tonato M
- Issue date: 1996 May
- Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.
- Authors: Thatcher N, Anderson H, Betticher DC, Ranson M
- Issue date: 1995 Dec
- Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer.
- Authors: Paesmans M
- Issue date: 2002 Jul